NEWS - Introducing the AEROECLIPSE II BAN


NEWS from Trudell Medical International^*
www.trudellmed.com		June 2007
AEROECLIPSE* II Breath Actuated Nebulizer (BAN) Study Summary		INTRODUCING THE AEROECLIPSE* II Breath Actuated Nebulizer Trudell Medical International is pleased to announce the launch of the AEROECLIPSE* II Breath Actuated Nebulizer (BAN) – the most significant advancement in the history of small volume nebulizers. The AEROECLIPSE* II BAN is designed to deliver superior, assured aerosol performance. Clinicians can be confident that the dose prescribed is the dose delivered, as aerosol is only generated in response to the patient’s inspiratory maneuver. The AEROECLIPSE* II BAN emits significantly lower levels of fugitive emissions (compared to continuous nebulizers) during exhalation or at rest which may provide for a safer healthcare and patient environment.^1,2 “It is important for respiratory therapists and other medical professionals to recognize and understand the possible respiratory effects related to the administration of aerosolized substances and take appropriate steps to minimize their exposure to these medications during patient diagnostic procedures and treatments.”¹ The AeroControl* System Regulator (SR) provides true breath actuation for patient on-demand therapy by allowing aerosol to be created during inhalation, but not during exhalation. Unlike other nebulizers, the AeroControl* SR ensures that very minimal drug aerosol escapes into the environment, ensuring: clinical dose assurance environmental protection for caregivers and healthcare providers less wasted medication Superior Aerosol Performance means shorter treatment times with the likelihood of better patient care and outcomes, because medication is delivered where it is needed most…deep into the lungs. If you have any questions about the new AEROECLIPSE* II BAN, please contact us using the information below: customerservice@trudellmed.com Phone Number +519-455-7060 Fax Number +519-455-7858 ¹ Respiratory Therapists Twice as Likely to Have Asthma Than Other Therapists – Exposure to Patient Treatments May Increase Therapists’ Asthma Risk, Canadian Society of Respiratory Therapists News, Oct. 2004. ² Carnathan B, Martin B, Colice G. Second Hand (S)-Albuterol: RT Exposure Risk Following Racemic Albuterol. Respiratory Care, October 2001, Vol. 46, No. 10 * Trade marks and registered trade marks of Trudell Medical International © Trudell Medical International 2007. All rights reserved. Privacy Policy MD-621A-0607